Portfolio
Portfolio

Dezima Pharma

Novel compounds to treat cardiovascular disease related to dyslipidemia.

Dezima Pharma develops novel compounds to treat cardiovascular disease related to dyslipidemia. Dezima's TULIP study was published in The Lancet in June 2015. On September, 16, 2015, Amgen agreed to acquire all outstanding shares of Dezima for up to US$1.55 billion.

  • Industry Biotech
  • History M&A